Literature DB >> 19347964

Description and validation of high-throughput simultaneous genotyping and mutation scanning by high-resolution melting curve analysis.

Tú Nguyen-Dumont1, Florence Le Calvez-Kelm, Nathalie Forey, Sandrine McKay-Chopin, Sonia Garritano, Lydie Gioia-Patricola, Deepika De Silva, Ron Weigel, Suleeporn Sangrajrang, Fabienne Lesueur, Sean V Tavtigian.   

Abstract

Mutation scanning using high-resolution melting curve analysis (HR-melt) is an effective and sensitive method to detect sequence variations. However, the presence of a common SNP within a mutation scanning amplicon may considerably complicate the interpretation of results and increase the number of samples flagged for sequencing by interfering with the clustering of samples according to melting profiles. A protocol describing simultaneous high-resolution gene scanning and genotyping has been reported. Here, we show that it can improve the sensitivity and the efficiency of large-scale case-control mutation screening. Two exons of ATM, both containing an SNP interfering with standard mutation scanning, were selected for screening of 1,356 subjects from an international breast cancer genetics study. Asymmetric PCR was performed in the presence of an SNP-specific unlabeled probe. Stratification of the samples according to their probe-target melting was aided by customized HR-melt software. This approach improved identification of rare known and unknown variants, while dramatically reducing the sequencing effort. It even allowed genotyping of tandem SNPs using a single probe. Hence, HR-melt is a rapid, efficient, and cost-effective tool that can be used for high-throughput mutation screening for research, as well as for molecular diagnostic and clinical purposes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347964      PMCID: PMC3478947          DOI: 10.1002/humu.20949

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  25 in total

1.  Global analysis of ATM polymorphism reveals significant functional constraint.

Authors:  Y R Thorstenson; P Shen; V G Tusher; T L Wayne; R W Davis; G Chu; P J Oefner
Journal:  Am J Hum Genet       Date:  2001-07-03       Impact factor: 11.025

2.  Simultaneous mutation scanning and genotyping by high-resolution DNA melting analysis.

Authors:  Jesse Montgomery; Carl T Wittwer; Robert Palais; Luming Zhou
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting.

Authors:  Michael T Seipp; Jacob D Durtschi; Michael A Liew; Jamie Williams; Kristy Damjanovich; Genevieve Pont-Kingdon; Elaine Lyon; Karl V Voelkerding; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

4.  Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms.

Authors:  Kim De Leeneer; Ilse Coene; Bruce Poppe; Anne De Paepe; Kathleen Claes
Journal:  Clin Chem       Date:  2008-04-10       Impact factor: 8.327

5.  ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.

Authors:  J Brunet; S Gutiérrez-Enríquez; A Torres; V Bérez; S Sanjosé; J Galceran; A Izquierdo; J A Menéndez; J Gumà; J Borràs
Journal:  Clin Genet       Date:  2008-04-02       Impact factor: 4.438

6.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.

Authors:  Anthony Renwick; Deborah Thompson; Sheila Seal; Patrick Kelly; Tasnim Chagtai; Munaza Ahmed; Bernard North; Hiran Jayatilake; Rita Barfoot; Katarina Spanova; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-07-09       Impact factor: 38.330

7.  Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer.

Authors:  L Izatt; J Greenman; S Hodgson; D Ellis; S Watts; G Scott; C Jacobs; R Liebmann; M J Zvelebil; C Mathew; E Solomon
Journal:  Genes Chromosomes Cancer       Date:  1999-12       Impact factor: 5.006

8.  The spectrum of ATM missense variants and their contribution to contralateral breast cancer.

Authors:  Annegien Broeks; Linde M Braaf; Angelina Huseinovic; Marjanka K Schmidt; Nicola S Russell; Flora E van Leeuwen; Frans B L Hogervorst; Laura J Van 't Veer
Journal:  Breast Cancer Res Treat       Date:  2007-03-28       Impact factor: 4.872

9.  Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.

Authors:  Elena A Takano; Gillian Mitchell; Stephen B Fox; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2008-02-25       Impact factor: 4.430

10.  Association of common ATM variants with familial breast cancer in a South American population.

Authors:  Patricio González-Hormazábal; Teresa Bravo; Rafael Blanco; Carlos Y Valenzuela; Fernando Gómez; Enrique Waugh; Octavio Peralta; Waldo Ortuzar; Jose M Reyes; Lilian Jara
Journal:  BMC Cancer       Date:  2008-04-23       Impact factor: 4.430

View more
  17 in total

1.  The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.

Authors:  Kiyoaki Ito; Katsuya Higami; Naohiko Masaki; Masaya Sugiyama; Motokazu Mukaide; Hiroaki Saito; Yoshihiko Aoki; Yo Sato; Masatoshi Imamura; Kazumoto Murata; Hideyuki Nomura; Shuhei Hige; Hiroshi Adachi; Keisuke Hino; Hiroshi Yatsuhashi; Etsuro Orito; Satomi Kani; Yasuhito Tanaka; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2011-03-09       Impact factor: 5.948

2.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

Authors:  Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2009-09-24       Impact factor: 11.025

3.  Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Authors:  Daniel J Park; Kayoko Tao; Florence Le Calvez-Kelm; Tu Nguyen-Dumont; Nivonirina Robinot; Fleur Hammet; Fabrice Odefrey; Helen Tsimiklis; Zhi L Teo; Louise B Thingholm; Erin L Young; Catherine Voegele; Andrew Lonie; Bernard J Pope; Terrell C Roane; Russell Bell; Hao Hu; Chad D Huff; Jonathan Ellis; Jun Li; Igor V Makunin; Esther M John; Irene L Andrulis; Mary B Terry; Mary Daly; Saundra S Buys; Carrie Snyder; Henry T Lynch; Peter Devilee; Graham G Giles; John L Hopper; Bing-Jian Feng; Fabienne Lesueur; Sean V Tavtigian; Melissa C Southey; David E Goldgar
Journal:  Cancer Discov       Date:  2014-05-02       Impact factor: 39.397

4.  A PALB2 mutation associated with high risk of breast cancer.

Authors:  Melissa C Southey; Zhi L Teo; James G Dowty; Fabrice A Odefrey; Daniel J Park; Marc Tischkowitz; Nelly Sabbaghian; Carmel Apicella; Graham B Byrnes; Ingrid Winship; Laura Baglietto; Graham G Giles; David E Goldgar; William D Foulkes; John L Hopper
Journal:  Breast Cancer Res       Date:  2010-12-23       Impact factor: 6.466

5.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.

Authors:  Florence Le Calvez-Kelm; Fabienne Lesueur; Francesca Damiola; Maxime Vallée; Catherine Voegele; Davit Babikyan; Geoffroy Durand; Nathalie Forey; Sandrine McKay-Chopin; Nivonirina Robinot; Tù Nguyen-Dumont; Alun Thomas; Graham B Byrnes; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian
Journal:  Breast Cancer Res       Date:  2011-01-18       Impact factor: 6.466

6.  Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.

Authors:  Tú Nguyen-Dumont; Lars P Jordheim; Jocelyne Michelon; Nathalie Forey; Sandrine McKay-Chopin; Olga Sinilnikova; Florence Le Calvez-Kelm; Melissa C Southey; Sean V Tavtigian; Fabienne Lesueur
Journal:  BMC Med Genomics       Date:  2011-05-11       Impact factor: 3.063

7.  Rapid and inexpensive body fluid identification by RNA profiling-based multiplex High Resolution Melt (HRM) analysis.

Authors:  Erin K Hanson; Jack Ballantyne
Journal:  F1000Res       Date:  2013-12-20

8.  Identification and Association of SNPs in TBC1D1 Gene with Growth Traits in Two Rabbit Breeds.

Authors:  Zhi-Juan Yang; Lu Fu; Gong-Wei Zhang; Yu Yang; Shi-Yi Chen; Jie Wang; Song-Jia Lai
Journal:  Asian-Australas J Anim Sci       Date:  2013-11       Impact factor: 2.509

9.  RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.

Authors:  Florence Le Calvez-Kelm; Javier Oliver; Francesca Damiola; Nathalie Forey; Nivonirina Robinot; Geoffroy Durand; Catherine Voegele; Maxime P Vallée; Graham Byrnes; Breast Cancer Family Registry; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian; Fabienne Lesueur
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

10.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.

Authors:  Francesca Damiola; Maroulio Pertesi; Javier Oliver; Florence Le Calvez-Kelm; Catherine Voegele; Erin L Young; Nivonirina Robinot; Nathalie Forey; Geoffroy Durand; Maxime P Vallée; Kayoko Tao; Terrell C Roane; Gareth J Williams; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; David E Goldgar; Fabienne Lesueur; Sean V Tavtigian
Journal:  Breast Cancer Res       Date:  2014-06-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.